Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer

Masahito Kotaka¹
Fusao Ikeda²
Masaki Tsujie³
Shinichi Yoshioka⁴
Yoshihiko Nakamoto⁵
Takaaki Ishii⁶
Takahisa Kyogoku⁷
Takeshi Kato⁸
Akihito Tsuji⁹
Michiya Kobayashi¹⁰

¹Gastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, ²Department of Surgery, Kohka Public Hospital, Koka, Shiga, ³Department of Colorectal Surgery, Sakai City Medical Center, Sakai, Osaka, ⁴Department of Surgery, Nishihara Hospital, Nishinomiyaya, Hyogo, ⁵Department of Surgery, Seikei-kai Chiba Medical Center, Chiba, Chiba, ⁶Department of Surgery, Kobe-Ekisaikai Hospital, Kobe, Hyogo, ⁷Department of Surgery, Nishikobe Medical Center, Kobe, Hyogo, ⁸Department of Colorectal Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, ⁹Kagawa University Hospital Cancer Center, Kita-gun, Kagawa, ¹⁰Department of Human Health and Medical Sciences, Kochi Medical School, Kochi University, Nangoku, Kochi, Japan

Background: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity.

Patients and methods: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years.

Results: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure was 5.3 months, the median PFS and OS were 5.3, 13.3, and 38.9 months, respectively.

Conclusion: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients.

Keywords: observational cohort study, metastatic colorectal cancer, XELOX plus bevacizumab, treatment continuity

Introduction

There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer (mCRC) due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody.¹⁻⁶ Recently, there have been additional advances with the advent of new drugs, such as regorafenib and TAS-102.⁷⁻¹¹ Several randomized clinical studies have been performed to identify the optimal combination of these drugs for use as first-line treatment.⁹⁻¹¹ It is important to continue first-line treatment and prolong progression-free survival (PFS) to improve the rate of overall survival (OS) as a true endpoint in the treatment of mCRC.
PFS is a surrogate endpoint for OS for mCRC. The French clinical study group GERCOR conducted the OPTIMOX 1 study to assess planned discontinuation and reintroduction of oxaliplatin in a stop-and-go strategy, and the OPTIMOX 2 study to evaluate the role of chemotherapy-free intervals (CFI), known as “chemotherapy holidays”. First-line treatment strategy with maintenance therapy has also been evaluated. In the CAIRO 3 study and the AIO KRK 0207 study, maintenance therapy with fluoropyrimidine-based chemotherapy plus bevacizumab and observation were compared in patients with mCRC without disease progression after a certain number of cycles of oxaliplatin-based chemotherapy with bevacizumab.

It is important to consider the treatment strategy to maintain the duration of first-line treatment, which leads to improved PFS and OS in patients with mCRC. We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated mCRC to investigate treatment continuity in daily clinical practice.

**Patients and methods**

This was a prospective observational cohort study to investigate the data from consecutive patients treated with XELOX plus bevacizumab during a certain period in several institutions in Japan.

This study was conducted in compliance with the Declaration of Helsinki and the Ethical Guidelines on Clinical Studies after receiving approval from the ethics committees of all participating institutions (Sano Hospital, Kobe City Medical Center West Hospital, Kobe-Ekisaikai Hospital, Nishikobe Medical Center, and Hyogo Prefectural Nishinomiya Hospital). Written informed consent was obtained from all patients before enrollment. The study registration was as follows: University Hospital Medical Information Network Clinical Trials Registry (UMIN000003416).

**Patient selection**

The inclusion criteria were as follows regardless of sex and age:
1. mCRC confirmed cytologically and/or histologically
2. lesions evaluable by imaging
3. previously untreated (except for surgery)
4. suitable condition to receive XELOX plus bevacizumab
5. written informed consent.

The exclusion criteria were as follows:
1. other active malignancies (ie, diagnosed within 5 years)
2. contraindications for bevacizumab, oxaliplatin, and capecitabine
3. considered unsuitable for the study by the investigators.

**Treatment**

Each patient received XELOX plus bevacizumab. On day 1, bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m²) were injected intravenously. From day 1 to day 14, capecitabine (2,000 mg/m²/day) was orally administered. Each cycle was repeated every 3 weeks.

Laboratory test including serological tumor marker was repeated for every cycle, and adverse event grades were evaluated in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.

Tumor assessment was repeated every 8 (±2) weeks using the same radiological imaging as baseline, basically using the contrast enhanced computed tomography (chest, abdominal, and pelvic), and assessed by the investigator based on the Response Evaluation Criteria in Solid Tumors, version 1.0.

**Statistical considerations**

The outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure (TTF), PFS, and OS.

Forty patients were enrolled and followed up for 2 years.

TTF was defined as the time from treatment initiation to disease progression or death from any cause or treatment discontinuation before completion, whichever was earlier. PFS was defined as the time from treatment initiation to disease progression or death from any cause, whichever was earlier. OS was defined as the time from treatment initiation to death from any cause.

TTF, PFS, and OS were estimated using the Kaplan–Meier method.

**Results**

Between July 2010 and June 2012, 40 patients were registered in this study from five institutions in Japan.

**Patient characteristics**

Of the 40 patients, 24 were male, and their median age was 63 years (range 35–84 years). The numbers of patients with the ECOG Performance Status 0, 1, and 2 were 33, 6, and 1, respectively; 24 patients had colon cancer; the primary tumor was resected in 35 patients before the commencement of XELOX plus bevacizumab; 23 patients had liver metastases; 16 had lung metastases; four had lymph node metastases; seven had peritoneal metastases; seven had other site metastases; 14 had wild-type KRAS Exon 2 tumor; 15 had mutant KRAS Exon 2 tumor; and eleven were untested.
Treatment continuity

Figure 1 shows treatment continuities of XELOX plus bevacizumab in the 40 patients. The median number of treatment cycles was 7.5 (range 2–40). The reasons for treatment discontinuation were as follows: complete response (CR), five patients (12.5%); resection, ten patients (25%); disease progression, 15 patients (37.5%); adverse events, seven patients (17.5%); and patient refusal, three patients (7.5%).

Among the seven patients who discontinued treatment due to adverse events, two discontinued due to grade 2 peripheral neuropathy, two due to grade 2 allergy, one due to both grade 3 hypertension and grade 2 allergy, one due to grade 3 nausea and anorexia, and one due to grade 2 hand–foot syndrome, respectively. Otherwise, no noteworthy adverse events happened and were reported to continue treatment with XELOX plus bevacizumab.

Figure 2 shows the details of a patient who discontinued treatment because of radiological CR. He was a 35-year-old man with synchronous liver metastases from colon cancer, who started treatment with XELOX plus bevacizumab after colorectomy, and achieved a partial response after two cycles and CR after 17 cycles. He had a PFS of 39 months after the initiation of XELOX plus bevacizumab.

Figure 3 shows the details of a patient who continued treatment until resection. She was a 60-year-old woman with metachronous paraaortic lymph node metastases from rectal cancer, who achieved a partial response after four cycles of XELOX plus bevacizumab, underwent resection of paraaortic lymph node metastases, and achieved pathological CR. She had a disease-free survival of 30 months after XELOX plus bevacizumab initiation.

Treatment outcome

The overall response rate was 57.5% (CR, seven patients [17.5%]; partial response, 16 patients [40.0%]). Ten patients had stable disease (25.0%), five had progression disease (PD) (12.5%), and two were not evaluated (5.0%).

The resection rate was 25.0% (liver metastases in six patients, lung metastases in two patients, paraaortic lymph node metastases in one patient, and local recurrence in one patient) and the liver resection rate was 15.0% (six patients).

After a median follow-up period of 31.4 months (range 0.7–50.9 months), the median TTF, PFS, and OS were, respectively, 5.3 months (95% confidence interval [CI], 3.6–9.1 months) (Figure 4), 13.3 months (95% CI,
**Figure 2** Case 1 (#20): liver metastases from colon cancer in a 35-year-old man.
*Abbreviations:* BV, bevacizumab; Pr, partial response; CT, computed tomography; cr, complete response; MRI, magnetic resonance imaging.

**Figure 3** Case 2 (#39): paraaortic lymph node metastases from rectal cancer in a 60-year-old woman.
*Note:* Red circles indicate metastases.
*Abbreviations:* BV, bevacizumab; Pr, partial response; CT, computed tomography; PCR, polymerase chain reaction.
9.8–18.2 months) (Figure 5), and 38.9 months (95% CI, 23.5 months to not reached) (Figure 6).

**Discussion**

This study was performed to evaluate treatment continuity for mCRC patients with introduction of maintenance therapy in daily clinical practice.

The overall treatment outcome of XELOX plus bevacizumab is almost similar to that of the previous studies. The overall response rate, 57.5%, is consistent compared to NO16966 (47%; XELOX ± bevacizumab) and JO19380 (72%; XELOX + bevacizumab). The median PFS and OS (13.3 and 38.9 months, respectively) tend to be slightly improved compared to NO16966 (8.0 and 19.8 months; XELOX ± bevacizumab) and JO19380 (11.0 and 27.4 months; XELOX + bevacizumab).

The median number of treatment cycles was 7.5, and only 14 patients (35%) were treated with capecitabine for maintenance therapy with or without bevacizumab followed by induction of XELOX plus bevacizumab. Among 20 patients who received eight or more cycles of XELOX plus bevacizumab, eleven patients (55%) received maintenance therapy with capecitabine with or without bevacizumab. Among 20 patients who received seven or fewer cycles, secondary resection was performed in nine patients (45%) (Figure 1).

It is important to continue first-line treatment and prolong PFS to improve OS in patients with mCRC. Therefore, the following two treatment strategies may be useful: 1) discontinuation of a cytotoxic agent and switch from induction to maintenance therapy, and 2) a chemotherapy holiday.

The French clinical study group GERCOR conducted the OPTIMOX 1 study to assess planned discontinuation and reintroduction of oxaliplatin in a stop-and-go strategy, and the OPTIMOX 2 study to evaluate the role of a chemotherapy holiday. The OPTIMOX 1 study compared FOLFOX4 until progression with FOLFOX7 for six cycles, followed by maintenance therapy with 5-FU/LV alone and reintroduction of FOLFOX7. Median duration of disease control, a primary endpoint in this study, was 9.0 months in patients treated with continuous FOLFOX4, compared with 10.4 months in patients treated with intermittent FOLFOX7 in a stop-and-go strategy (P=0.89). This study showed no difference in efficacy between continuous chemotherapy and intermittent chemotherapy with maintenance therapy. On the other hand, the OPTIMOX 2 study compared mFOLFOX7 for six cycles followed by maintenance with leucovorin-5-fluorouracil alone (maintenance arm), with mFOLFOX7 for six cycles followed by complete cessation of chemotherapy (CFI arm). Median duration of disease control was 13.1 months in patients assigned to the maintenance arm, and 9.2 months in patients assigned to the CFI arm (P=0.046). This study indicated that planned complete discontinuation of chemotherapy had a negative impact on treatment efficacy.
Maintenance therapy for mCRC was developed after these two studies involving bevacizumab.

In a phase III study, NO16966, which evaluated the efficacy and safety of bevacizumab added to FOLFOX4 or XELOX as first-line treatment for mCRC, the addition of bevacizumab significantly improved PFS but the effect size was slightly smaller than expected (9.4 months vs 8.0 months, hazard ratio (HR) = 0.83; P=0.0023). This was considered to be because the duration of bevacizumab treatment in NO16966 was shorter than in the previous study, and there was a lack of treatment with bevacizumab until PD.3 On the other hand, in a randomized phase II study, CONCePT, in which patients were randomized to receive cycles of modified FOLFOX7 plus bevacizumab with eight-cycle blocks of oxaliplatin vs continuous oxaliplatin, when bevacizumab treatment added to oxaliplatin-based chemotherapy was sufficiently continued, it improved PFS (median TTF 5.7 months vs 4.2 months; median PFS 12.0 months vs 7.4 months).30 As lessons from NO16966 and CONCePT, the early treatment discontinuation or complete stop for reasons other than disease progression should be avoided as far as possible.3,20

Several studies of bevacizumab maintenance therapy have been reported. The CAIRO 3 study demonstrated the superiority of maintenance therapy with capecitabine and bevacizumab toward the observation, after induction therapy with six 3-weekly cycles of XELOX plus bevacizumab. The primary endpoint of median PFS2 was 11.7 months in patients with maintenance therapy, and 8.5 months in patients with observation (P<0.0001).35 In addition, the AIO KRK 0207 study denied the non-inferiority of the observation toward maintenance with fluoropyrimidine-based chemotherapy and bevacizumab, after a 24-week induction therapy with oxaliplatin-based chemotherapy and bevacizumab. The primary endpoint of median time to failure of strategy was 6.1 months in patients with observation, and 6.8 months in patients with maintenance (P=0.11; HR =1.22 [95% CI, 0.96–1.57]; non-inferiority margin HR =1.466).17

In this cohort of 40 patients treated with XELOX plus bevacizumab, 14 patients (35.0%) received a certain number of cycles of XELOX plus bevacizumab followed by maintenance with capecitabine plus bevacizumab or capecitabine alone. However, among 20 patients who received eight or more cycles of XELOX plus bevacizumab, eleven patients (55%) received maintenance therapy with capecitabine plus bevacizumab or capecitabine alone (Figure 1). Among these eleven patients, seven were treated until PD, and treatment was discontinued in two patients due to radiological CR. Among the remaining nine patients (45%) who were not treated with maintenance therapy, three were treated until PD, two discontinued treatment due to radiological CR, and one underwent resection due to response to XELOX plus bevacizumab.

On the other hand, the “planned” strategy of treatment discontinuation or CFI for mCRC cannot be conducted, but CFI or chemotherapy holiday as a result of treatment discontinuation for mCRC cannot be conducted, such as radiological CR or metastasectomy, plays a crucial role in improving survival of patients with mCRC.

Adam et al21 reported that the 5-year survival rate was 33% in patients with colorectal liver metastases who were assessed as initially unresectable but reassessed as resectable after response to chemotherapy and underwent secondary hepatic resections, although the 5-year survival rate was 0% to 5% in patients with unresectable mCRC. Recently, the CALGB/SWOG 80405 study reported that 132 patients underwent hepatic resections and had no evidence of disease, among 1,137 patients enrolled in the study with unresectable mCRC with wild-type KRAS Exon 2 tumor, but resection of metastases was intended as a result of tumor response in 15% of these patients.22 The median OS of these 132 patients was 64.7 months. Moreover, in both the BOXER study, a phase II study of XELOX plus bevacizumab for liver-limited metastases (LLD) from colorectal cancer, and the CELIM study, a phase II study of FOLFOX/FOLFIRI plus cetuximab for LLD, favorable long-term survival was reported for patients with initially unresectable LLD who responded to chemotherapy and underwent curative secondary resection, although tumor recurrence inevitably occurred.23,24 In the CELIM study, the median OS was 53.9 months, while the median PFS was 15.4 months for 36 patients for whom curative secondary resections were performed.24 Thus, a CFI or chemotherapy holiday as a result of tumor response to chemotherapy and hepatectomy contributes to improvement of survival.

In this cohort of 40 patients treated with XELOX plus bevacizumab, among 20 patients who received seven or fewer cycles of XELOX plus bevacizumab, nine patients (45%) underwent resection as a result of response to XELOX plus bevacizumab. In this cohort study, the median PFS and OS were increased to 13.3 and 38.9 months, respectively, although the median TTF was 5.3 months. This may have resulted from the CFI in these nine patients for whom secondary resection was performed.

This observational cohort study investigated treatment continuity among 40 consecutive patients treated with...
XELOX plus bevacizumab in daily clinical practice. As reported in previous clinical studies, maintenance therapy with capecitabine plus bevacizumab plays an important role in treatment continuity and efficacy, and CFI or chemotherapy holiday resulting from radiological CR or metastasectomy prolonged the PFS and thus improved OS.

Acknowledgments
The authors thank the following institutions for their cooperation with enrollment and data follow-up: Sano Hospital, Kobe City Medical Center West Hospital, Kobe-Esakaikai Hospital, Nishikobe Medical Center, and Hyogo Prefectural Nishinomiya Hospital.

The authors also thank Taro Ikumoto from Sano Hospital; Atushi Itami and Saori Goto (now moved to Kyoto University) from Nishikobe Medical Center; and Ryuichi Mikami and Hiroyuki Kayada from Kobe City Medical Center West Hospital especially for their cooperation with data collection. The abstract of this paper was presented at the Gastrointestinal Cancers Symposium, January 16–18, 2014, in San Francisco as a poster presentation with interim findings. The abstract of the poster was published in J Clin Oncol 2014, 32:3s (suppl; abstr 661): http://meeting.ascpubs.org/cgi/content/short/32/3_suppl/661.

Disclosure
MK received honoraria from Chugai Pharmaceutical, Yakult Honsha, Merck, and Takeda. TK received honoraria from Chugai Pharmaceutical, Yakult Honsha, Merck, Takeda, Taiho, Bayer, and Eli Lilly. AT received honoraria from Chugai Pharmaceutical, Yakult Honsha, Merck, Bristle-Myers Squibb, Takeda, and Taiho.

The other authors report no conflicts of interest in this work.

References
9. Venzonok AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5FU/leucovorin (FOLFIRI) or oxaliplatin/5FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CT) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc Am Soc Clin Oncol 2014;32(suppl 5):LB1A3 (abstr).
